1. What minimum duration of remission or low disease activity is suggested before considering tapering DMARDs?
2. Why might dose escalation of methotrexate be considered after initial prescribing according to the guideline?
3. When should prior DMARD regimens be reinstituted during tapering?
4. In patients on combination therapy with methotrexate plus a bDMARD or tsDMARD who wish to discontinue a DMARD, which agent is preferred for gradual discontinuation?
5. What are bDMARDs and tsDMARDs, and how do they differ in the treatment of rheumatoid arthritis?
6. What is the rationale for recommending abatacept over other bDMARDs or tsDMARDs in patients with NTM lung disease?
7. How should treatment be adjusted in patients taking TNF inhibitors who develop heart failure?
8. How should methotrexate intolerance be managed before switching to alternative DMARDs?
9. For patients taking methotrexate plus a biologic or targeted synthetic DMARD who want to discontinue a DMARD, which agent is conditionally recommended to be discontinued gradually?
10. What are the considerations for DMARD use in rheumatoid arthritis patients with solid malignancies according to current guidelines?
11. In patients with nontuberculous mycobacterial lung disease and moderate-to-high disease activity, which DMARD class is conditionally recommended over others?
12. What are the recommendations for methotrexate administration routes in patients starting treatment?
13. Why are specific recommendations lacking for rheumatoid arthritis patients receiving checkpoint inhibitor therapy?
14. Among DMARD-naive patients with low disease activity, which csDMARD is conditionally recommended over others due to better tolerability and risk profile?
15. What are the potential disadvantages of combination csDMARD therapy that influence the recommendation favoring methotrexate monotherapy?
16. How should patients with a serious infection within the previous 12 months and moderate-to-high disease activity despite csDMARD monotherapy be managed in terms of adding DMARDs?
17. What is the recommendation regarding the use of intraarticular glucocorticoids alone versus adding or switching DMARDs for patients not at target?
18. How does the guideline recommend using a treat-to-target (TTT) approach in patients who have not previously been treated with biologic or targeted synthetic DMARDs?
19. Why is methotrexate monotherapy conditionally recommended over combination csDMARD therapy in early rheumatoid arthritis?
20. Under what circumstances is a bDMARD or tsDMARD typically added to methotrexate therapy?